Galantamine and wedelolactone combined treatment suppresses LPS-induced NLRP3 inflammasome activation in microglial cells
The concurrent administration of galantamine and wedelolactone effectively suppresses the production of inflammatory cytokines and NLRP3 inflammasome activation in microglia. This inhibitory effect is likely linked to the NF-κB signaling pathway modulation. Therefore, this combined treatment is a potential therapeutic approach for neuroinflammatory diseases.
Authors
- Sait Polat (ORCID: https://orcid.org/0000-0003-1646-8831)
- Leman Sencar (ORCID: https://orcid.org/0000-0002-6301-0308)
- Tuğçe Sapmaz Erçakallı
- Dilek Şaker (ORCID: https://orcid.org/0000-0002-5055-4226)
- Gülfidan Çoşkun (ORCID: https://orcid.org/0000-0001-8219-2816)
- Derviş Yılmaz (ORCID: https://orcid.org/0000-0002-2246-1735)
Institutions
- Department of Embryology (US)
- Cukurova University (TR)
Publication Details
- Journal
- Immunopharmacology and Immunotoxicology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1080/08923973.2024.2405579
- Citations
- 2
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.49